DRD2 and small cell lung carcinoma: Our immunofluorescence results showed no statistically significant changes in endothelial D2R expression upon cisplatin/etoposide treatment between chemotherapy-naïve and chemotherapy-resistant SCLC PDXs (see cisplatin/etoposide treated group in Fig. 7d; Supplementary Fig. 9).